Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915025 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
A Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Imunon.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 7
- Study locations
NCT06915025 is a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by Imunon. The registered enrollment target is 500 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (31% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT06915025, a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by Imunon.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Olaparib
- DRUG Paclitaxel
- DRUG Niraparib
- DRUG IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
Study Locations (7)
Florida
- Advent Health - Orlando
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Oregon
- Providence Cancer Institute - Portland
South Dakota
- Sanford Health - Sioux Falls
Tennessee
- Erlanger Health - Chattanooga
Washington
- Providence Sacred Heart Medical Center & Children's Hospital - Spokane
Wisconsin
- Froedtert and The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2032-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06915025
The ClinicalTrials.gov registry entry for NCT06915025 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (31% lower). The listed sponsor is Imunon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06915025 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Florida, Missouri, Oregon.
Frequently Asked Questions
What is clinical trial NCT06915025 about?
NCT06915025 is a clinical study titled "Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer". This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
What is the current status of trial NCT06915025?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-07-09. Estimated completion is 2032-10-31.
What conditions does trial NCT06915025 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma.
What interventions are being tested in trial NCT06915025?
The interventions under investigation include: Carboplatin (DRUG), Olaparib (DRUG), Paclitaxel (DRUG), Niraparib (DRUG), IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) (DRUG).
Who is sponsoring clinical trial NCT06915025?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915025 being conducted?
This trial has 7 study locations across Florida, Missouri, Oregon, South Dakota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.